Zihao Huang

Zihao Huang

Auto-generated profile, based on publicly available information

Zihao Huang

Department of Rehabilitation Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
PDF file
ZHZihao Huang
Zihao Huang
RHRihua Huang
Rihua Huang
XXXinghao Xu
Xinghao Xu
ZFZiyan Fan
Ziyan Fan
ZXZhenyu Xiong
Zhenyu Xiong
XZXiao-dong Zhuang
Xiao-dong Zhuang
Maintaining long-term guidelines-recommended PA levels may decrease the risk of cardiovascular events in later life, and young adults maintaining that PA level for at least 75% of time may be preferable. Bullet Points

14 March 2025 in JACC: Advances
Verified
Journal Article
Open access
ZHZihao Huang
Zihao Huang
XXXinghao Xu
Xinghao Xu
YLYan Leng
Yan Leng
ZKZezhi Ke
Zezhi Ke
ZTZiyue Tang
Ziyue Tang
QLQi Liang
Qi Liang
Among individuals with chronic heart failure with reduced ejection fraction (HFrEF), the predictive value for mortality by biomarker-based biological age (BA) and whether aerobic exercise training (AET) modifies the association are understudied. The authors aimed to investigate the association between BA and mortality among individuals with HFrEF and assess whether AET modifies the association. Including participants in HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), BA acceleration was constructed by the Klemera-Doubal method, using the residual of a linear model of BA and chronological age. The associations between BA and all-cause mortality, cardiovascular death, and all-cause hospitalization were investigated by treating BA acceleration into continuous and quintiles in the overall cohort. Among the 1,732 individuals, during a median of 31.5 (IQR: 20.7-43.1) months of follow-up, 301 deaths were observed. A 1-SD increase in BA acceleration was associated with a 31% higher risk of all-cause mortality (HR: 1.31; 95% CI: 1.13-1.51), a 31% higher risk of cardiovascular mortality (HR: 1.31; 95% CI: 1.12-1.54), and a 9% higher risk of all-cause hospitalization (HR: 1.09; 95% CI: 1.01-1.17). The association of all-cause mortality was significantly different between treatment arms (P interaction = 0.024). BA acceleration was associated with a 53% higher risk of all-cause mortality in usual care (HR: 1.53; 95% CI: 1.25-1.89), but the association was not significant in AET (HR: 1.10; 95% CI: 0.89-1.36). Among individuals with HFrEF, BA has a good prediction value in HFrEF endpoints. AET may be associated with a reduction in all-cause mortality driven by aging.